Towards the end of 2019, a novel coronavirus disease (COVID-19) was first reported in Wuhan, China, and has since been spreading rapidly and viciously across the nation.

With national cooperation, China has adopted a strict joint prevention and control policies, and after more than two months, the Country has managed to effectively control the outbreak. But outside its boarders, the epidemic has escalated, with the number of new cases and deaths exceeding Chinas domestic infections. Though there is a desperate need for anti-epidemic measures in various countries, there is also a severe global shortage of anti-epidemic materials. In these past two months, China has changed the situation of a serious shortage of domestic medical supplies, and has began exporting overseas, contributing to the fight against this global epidemic.

Amidst this battle, the mobilization ability of the Chinese government, the R&D of Chinese enterprises, the manufacturing and cross-border transformation capabilities are all commendable. From in vitro diagnostic tools to vaccines, advanced medical devices to cutting-edge cell therapy, a number of outstanding enterprises have emerged in the face of this arduous fight against the epidemic, including Meilleure Health and Sansure Biotech.

The COVID-19 detection kit was developed by Sansure Biotech in response to the outbreak, skillfully utilizing accumulated knowledge of technology from the past 10 years. The research and development of this detection kit was officially announced on January 14th, and became the first of six to pass the emergency examination and approval from the National Medical Products Administration (NMPA). It has now obtained the European Union CE certification and has started the United States FDA EUA (Emergency Use Authorization) application after their Pre-EUA approval. At present, detection kits have been supplied to more than 30 provinces in China and more than 40 countries and regions worldwide, used as an effective diagnosis and discharge assessment for COVID-19 infected cases.

After the first outbreak of COVID-19, Meilleure Health procured anti-epidemic resources from around the world, and donated the aids to various health care facilities. The resources were distributed to Renmin Hospital of Wuhan University, Xiangya Hospital in Hunan, Hunan medical aid teams, The Third People's Hospital of Shenzhen and other key epidemic areas. In February, the anti epidemic campaign resumed work and commenced production. Faced with shortage in supply of masks, Meilleure's subsidiary Meiray Vap transformed to accommodate mask production and undertake government orders. Since March, COVID-19 has entered the stage of a global pandemic and while China has effectively controlled the number of infected cases, a considerable effort from scientific, technological and manufacturing forces have to convene to win the fight against this disease. At this juncture, it is a new trend to export Chinese experience and materials to the world. Meilleure Health has efficiently started the relevant work to supply new COVID-19 detection kits, masks and other crucial anti-epidemic resources worldwide. This is the “anti-epidemic" trilogy of Meilleure as a global health enterprise, to reflect their active resilience and responsibility to the people in combat with this virus.

In this global fight against the pandemic, Meilleure Health will continue to take advantage of its international presence. The partnership with Sansure Biotech will utilize both companies’ advantages, to meet the supply shortage of anti-epidemic resources in countries and regions, to help combat COVID-19. Under the global community of healthy destiny, Meilleure builds the bridge for this vision.

Company Name: Meilleure Health International Industry Group

Person: Evan

Email: info@meilleure.com.cn

Website: http://meilleure.com.cn/